Microfluidic enrichment of plasma cells improves treatment of multiple myeloma
Cytogenetic alterations form the basis for risk stratification for multiple myeloma (MM) and guide the selection of therapy; however, current pathology assays performed on bone marrow samples can produce false‐negatives due to the unpredictable distribution and rarity of MM cells. Here, we report on...
Main Authors: | Yunjing Zeng, Li Gao, Xiaoqing Luo, Yan Chen, Mustafa H. Kabeer, Xuelian Chen, Andres Stucky, William G. Loudon, Shengwen C. Li, Xi Zhang, Jiang F. Zhong |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-06-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.12201 |
Similar Items
-
Corrigendum to: Microfluidic enrichment of plasma cells improves treatment of multiple myeloma
by: Yunjing Zeng, et al.
Published: (2021-01-01) -
Socioeconomic status-based survival disparities and nomogram prediction for patients with multiple myeloma: Results from American and Chinese populations
by: Jiaxuan Xu, et al.
Published: (2022-08-01) -
Risk Stratification and Treatment in Smoldering Multiple Myeloma
by: Tyler Lussier, et al.
Published: (2021-12-01) -
Application of clinical nomograms to predicting overall survival and event-free survival in multiple myeloma patients: Visualization tools for prognostic stratification
by: Jiaxuan Xu, et al.
Published: (2022-10-01) -
Testing Mayo Clinic’s New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study
by: Camille Tessier, et al.
Published: (2021-05-01)